Catalog No.
Product Name
Application
Product Information
Citations
-
IDO1 inhibitor
INCB024360 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase (IDO1), with potential immunomodulating and antineoplastic activities. -
hIDO2 inhibitor
GNF-PF-3777 (8-Nitrotryptanthrin) is a potent human indoleamine 2,3-dioxygenase 2 (hIDO2) inhibitor which significantly reduces IDO2 activity with Ki of 0.97 μM. -
IDO inhibitor
Indoximod is a methylated tryptophan with anti-immunosuppressive activity. -
IDO inhibitor
Epacadostat is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM, Phase 2,- Chunbo He, .et al. , Cancer Discov, 2024, Jan 12;14(1):176-193 PMID: 37931287
- Saeko Yoshioka, .et al. , Int J Tryptophan Res, 2022, Nov 30;15 PMID: 36467776
- Marta Galan-Diez, .et al. , Cancer Discov, 2022, Apr 1;12(4):1106-1127 PMID: 35046097
-
IDO1 inhibitor
BMS-986205, also known as Linrodostat, ONO-7701 and F001287, a potent and selective, orally active IDO1 inhibitor with potential immunomodulating and antineoplastic activities. CAS: 1923833-60-6 (free base) 2221034-29-1 (mesylate) -
IDO/TDO dual inhibitor
IDO/TDO-IN-1 is a highly potent and orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50s of 9.7 and 47 nM, respectively . -
IDO1 inhibitor
LY-3381916 is a potent, selective and brain penetrated inhibitor of IDO1 activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1. -
IDO-1 inhibitor
PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor with IC50s of 0.41 μM, 0.59 μM, and 1.5 μM for hIDO-1, dIDO-1, and mIDO-1, respectively. -
IDO-1 inhibitor
IDO-IN-4 is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1. -
dual IDO/TDO inhibitor
IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively. -
dual IDO/TDO inhibitor
IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively. -
IDO1 inhibitor
Navoximod, also known as IDO-IN-7 and NLG-1488, is an indoleamine 2,3-dioxygenase (IDO) inhibitor. -
PROTAC IDO1 Degrader
PROTAC IDO1 Degrader-1 is a novel compound targeting indoleamine 2,3-dioxygenase 1 (IDO1) through the engagement of Cereblon E3 ligase, facilitating its ubiquitination and subsequent degradation. With a reported DC50 of 2.84 μM, this degrader enhances the anti-tumor efficacy of HER2 CAR-T cells, making it a valuable tool for research in cancer immunotherapy and targeted degradation methods. Its ability to modulate IDO1 levels opens avenues for investigations into metabolic regulation and tumor microenvironment interactions. -
IDO Inhibitor
IDO1 and HDAC1 Inhibitor (Compound 10) is a dual-target inhibitor that effectively inhibits indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase 1 (HDAC1) with IC50 values of 69.0 nM and 66.5 nM, respectively. This compound demonstrates significant biological activity in modulating immune responses and epigenetic regulation. It is suitable for use in cancer research, immunotherapy studies, and investigations into the mechanistic roles of IDO1 and HDAC1 in various biological processes. -
IDO1/TrxR1 Inhibitor
ZC0109 is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1), exhibiting IC50 values of 50 nM and 3.0 μM, respectively. This compound is effective in inducing reactive oxygen species (ROS) accumulation and causing cell cycle arrest at the G1/S phase, ultimately leading to apoptosis in cancer cells. ZC0109 is a valuable reagent for research applications focused on cancer therapy and the modulation of immune response through IDO1 and TrxR1 inhibition. -
IDO-1/NS2B-NS3 Inhibitor
Palmatine is a selective, irreversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO-1), exhibiting IC50 values of 3 μM against HEK 293-hIDO-1 and 157 μM against rhIDO-1. Additionally, Palmatine effectively inhibits the West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. This compound demonstrates diverse biological activities including anti-cancer, anti-oxidation, anti-inflammatory, neuroprotective, antibacterial, and antiviral effects, making it a valuable tool for research in cancer biology, inflammation, and infectious diseases. -
IDO/Tubulin Inhibitor
IDO/Tubulin-IN-2 is a potent inhibitor targeting both indoleamine 2,3-dioxygenase (IDO) and tubulin. This compound exhibits significant anticancer activity, demonstrated by its effect on various cell lines, including U87, HepG2, A549, HCT-116, and LO2, with IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM, respectively. IDO/Tubulin-IN-2 is valuable for research applications in cancer biology, particularly in elucidating mechanisms of tumorigenesis and therapeutic resistance. -
IDO1/TrxR Inhibitor
ZC0101 is a potent dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase (TrxR), exhibiting IC50 values of 0.084 μM and 7.98 μM, respectively. This compound demonstrates significant biological activity by inducing apoptosis and promoting reactive oxygen species (ROS) accumulation in cancer cells. ZC0101 is a valuable tool for research applications aimed at understanding cancer cell metabolism and exploring therapeutic strategies targeting IDO1 and TrxR pathways. -
IDO Inhibitor
(Rac)-Indoximod is an indoleamine 2,3-dioxygenase (IDO) inhibitor that modulates immune responses. This compound synergizes with interferon-gamma (IFN-γ) to significantly decrease the activity of human cardiac myofibroblasts, characterized by α-SMA expression, and promotes apoptosis by upregulating the genes IRF-1, Fas, and FasL. Its applications include studying immune regulation and apoptosis in cardiac tissue and investigating therapeutic strategies for fibrotic diseases. -
IDO-1/NS2B-NS3 Inhibitor
Palmatine hydroxide is an irreversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO-1) with IC50 values of 3 μM and 157 μM against HEK 293-hIDO-1 and rhIDO-1, respectively. This compound also exhibits uncompetitive inhibition of the West Nile virus NS2B-NS3 protease with an IC50 of 96 μM. Palmatine hydroxide demonstrates a wide range of biological activities, including anti-cancer, anti-oxidation, anti-inflammatory, neuroprotective, antibacterial, and antiviral effects, making it a valuable tool for research in cancer therapy, viral infections, and oxidative stress-related studies. -
IDO1 Inhibitor
LW106 is a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 of 1.57 μM. It preferentially targets IDO1 without affecting IDO2 or tryptophan 2,3-dioxygenase (TDO). LW106 demonstrates antitumor activity by disrupting stroma-immune interactions and reducing the enrichment of cancer stem cells (CSCs) within the tumor microenvironment, leading to decreased tumor cell proliferation and increased apoptosis. This compound is suitable for research applications in lung cancer and melanoma. -
IDO/Tubulin Inhibitor
HI5 is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO) and tubulin, demonstrating an IC50 of 70 nM in HeLa cells. It effectively reduces kynurenine production, thereby promoting T cell activation and proliferation. Additionally, HI5 interferes with tubulin polymerization and migration, induces G2/M phase cell cycle arrest, and triggers apoptosis through a mitochondrial-dependent pathway, leading to increased reactive oxidative stress. HI5 is suitable for research in anticancer applications. -
IDO Inhibitor
Pronqodine A is an inhibitor of Indoleamine 2,3-Dioxygenase (IDO) with an IC50 of 131.5 nM. It effectively reduces bradykinin-induced release of PGE2, 6-keto-prostaglandin F1α, and PGD2, while simultaneously inducing reactive oxygen species (ROS) production in human synovial sarcoma SW982 cells. Additionally, Pronqodine A serves as a substrate for human quinone reductase NQO1, making it a valuable tool for research into inflammation and related biological processes. -
IDO1 Inhibitor
VS-15 is an IDO1 inhibitor that selectively binds to the heme-free form of IDO1, interrupting its enzymatic activity. This compound has been linked to the reduction of nitric oxide (NO) production, suggesting additional broad-spectrum inhibitory effects on iNOS. VS-15 is primarily utilized in research focused on immunomodulation and cancer therapy, making it a valuable tool for studies investigating the role of tryptophan metabolism in immune responses. -
IDO1 Inhibitor
IDO1-IN-30 is a selective and potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), demonstrating an IC50 of 4.8 nM in SKOV3 cells. This compound exhibits minimal cytotoxicity in HepG2 cells at concentrations up to 25 µM and does not significantly inhibit CYP450 enzymes, including 3A4, 2C9, and 2D6. IDO1-IN-30 is suitable for studies focused on cancer immunotherapy and the modulation of inflammatory responses. -
IDO1 Inhibitor
IDO1-IN-19 is a selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 value of 8.64 μM for CYP2C9. In addition, it modulates cardiac ion channels with IC50 values of 12 μM for IKr, 40 μM for INa, and 8.3 μM for ICa. This compound is valuable for investigating the mechanisms of cancer biology and has potential applications in cancer therapeutics. -
IDO1 Inhibitor
Amg-1 is a potent and reversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 3.0 μM. It demonstrates significant selectivity, with over 80-fold greater inhibition of IDO1 compared to IDO2 and over 20-fold selectivity against TDO. This compound is valuable for research in cancer, hypotension, and neurological disorders, facilitating the exploration of therapeutic strategies targeting immune regulation and metabolism. -
Apo-IDO1 Inhibitor
IDO1-IN-28 is an Apo-IDO1 inhibitor that disrupts heme binding with an IC50 of 1.29 μM. This compound selectively targets apo-IDO1, offering a valuable tool for studying its role in tumor immunology. IDO1-IN-28 is applicable in cancer research, facilitating investigations into the modulation of immune responses in various malignancies. -
IDO Inhibitor
(S)-Indoximod is a selective inhibitor of indoleamine 2,3-dioxygenase (IDO), with a Ki value of 19 μM. This compound has demonstrated notable biological activity in modulating immune responses and has potential applications in cancer research and the study of neurological disorders. Its ability to inhibit IDO activity makes it a valuable tool for investigating therapeutic strategies in various disease contexts. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-4 is a dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of 3.53 μM and 1.15 μM, respectively. It interacts with IDO1 through hydrogen bonding and engages TDO via π−π stacking interactions. This compound is valuable for investigating the role of IDO1/TDO in depression and related conditions, including infectious, metabolic, and autoimmune disorders. -
IDO1 Inhibitor
DP00477 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 value of 7.0 µM. This compound is valuable for investigating the role of IDO1 in tumor immune evasion and has potential applications in cancer research. Its inhibitory effects can facilitate studies on the modulation of the immune response in cancer therapy. -
IDO1 Inhibitor
IDO1-IN-18 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), a critical enzyme in tryptophan metabolism that plays a role in immune regulation and tumor immune evasion. This compound demonstrates significant biological activity in inhibiting IDO1, which may enhance anti-tumor immune responses. IDO1-IN-18 is valuable for research applications in cancer biology and immunology, particularly in studies exploring the modulation of immune responses in tumor microenvironments. -
IDO1/IDO2 Inhibitor
IDO1/2-IN-1 is a novel dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and IDO2, with IC50 values of 28 nM and 144 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. The orally active nature of IDO1/2-IN-1 enhances its potential for in vivo studies, facilitating the exploration of immunomodulatory effects and therapeutic applications in oncology. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-9 is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of less than 1 μM. This compound effectively inhibits the enzymatic activity of IDO1 and TDO, thereby blocking the degradation of tryptophan to kynurenine. By restoring immune activity within the tumor microenvironment, IDO1/TDO-IN-9 shows potential in suppressing tumor growth, making it a valuable tool for cancer research. -
IDO1 Inhibitor
4-Phenyl-1H-1,2,3-triazole is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 60 μM. This compound plays a crucial role in cancer research by modulating immune responses and inhibiting tumor-induced immune tolerance. Its ability to interfere with the kynurenine pathway makes it a valuable tool for studying tumor microenvironments and exploring new therapeutic strategies in oncology. -
IDO1 Inhibitor
BMS-986242 is a selective, orally active inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1). This compound demonstrates potent inhibition of IDO1 enzymatic activity, a critical pathway in the immunosuppressive tumor microenvironment. Research applications include exploring its use in combination therapies for cancer treatment and investigating its effects on immune response modulation. -
IDO Inhibitor
IDO2-IN-1 is a potent inhibitor of Indoleamine 2,3-dioxygenase 2 (IDO2), exhibiting an IC50 value of 112 nM. This compound is designed for use in research related to inflammatory autoimmunity, providing valuable insights into the mechanisms of immune modulation. Its ability to selectively inhibit IDO2 activity positions it as a crucial tool for exploring therapeutic strategies in related disease contexts. -
IDO Inhibitor
Kushenol E is a flavonoid derived from Sophora flavescens and acts as a non-competitive inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 of 7.7 µM and a Ki of 9.5 µM. This compound exhibits notable anti-tumor activity, making it relevant for research applications in cancer biology and immunotherapy. Its mechanism of action provides potential insights into immune modulation within the tumor microenvironment. -
IDO Inhibitor
IDO-IN-18 is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in the regulation of immune responses. By inhibiting IDO, this compound enhances T-cell activity and potentially mitigates immunosuppression in the context of infectious and cancer diseases. IDO-IN-18 is instrumental in research aimed at understanding immune modulation and developing therapeutic strategies for various malignancies and chronic infections. -
IDO1 Inhibitor
(S)-LY-3381916 is a selective inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1), demonstrating potent activity with an IC50 value of less than 1.5 µM. This S-isomer effectively binds to the apo-IDO1 form, targeting the enzyme in its unbound state and circumventing the heme-bound variant. Research applications include investigating the role of IDO1 in immunoregulation and exploring therapeutic strategies in cancer and inflammatory diseases.
